Loading…
Incannex Healthcare Inc. is projected to rise to $4.05 by 2027, a +25% move from its current price of $3.25. IXHL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.10 | $3.25 | $3.41 | -0.04% |
| May 30 | $3.03 | $3.25 | $3.48 | -0.08% |
| May 31 | $2.99 | $3.25 | $3.53 | -0.11% |
| Jun 1 | $2.95 | $3.25 | $3.57 | -0.15% |
| Jun 2 | $2.91 | $3.24 | $3.61 | -0.19% |
| Jun 3 | $2.88 | $3.24 | $3.65 | -0.23% |
| Jun 4 | $2.85 | $3.24 | $3.68 | -0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.24 | $3.68 | -0.26% |
| Week 2 | $2.70 | $3.23 | $3.87 | -0.53% |
| Week 3 | $2.59 | $3.22 | $4.02 | -0.79% |
| Week 4 | $2.49 | $3.22 | $4.15 | -1.05% |
| Week 5 | $2.41 | $3.21 | $4.26 | -1.31% |
| Week 6 | $2.34 | $3.20 | $4.37 | -1.57% |
| Week 7 | $2.28 | $3.19 | $4.47 | -1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
IXHL trades at $3.25 and has a market cap of $38.88M, ranking 4654. The current price and modest market position reflect a biotechnology/healthcare focus with an early-stage development portfolio.
The near-term outlook shows a neutral stance with a 2026 average price of $3.25, a low of $2.56 and a high of $5.35, and an expected ROI of 0. Sentiment for 2026 is NEUTRAL. The forecast path improves in subsequent years, with 2027 average $4.05 (ROI 24.5) and 2028 average $4.03 (ROI 24), followed by 2029 average $4.20 (ROI 29.2) as bullish momentum appears.
Longer-term projections show continued bullishness in later years, with 2034 average $5.59 (ROI 72.1) and 2035 average $5.43 (ROI 67.2), and notable growth into 2040 and beyond, including 2040 average $6.35 (ROI 95.4) and 2050 average $11.30 (ROI 247.7). The forecast includes a neutral stance for 2030–2032 and then a return to bullish sentiment in several later years, underscoring the volatility and upside potential of the asset.
A major floor 34.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 51.1% above — a clean break opens room to run.
A major ceiling 248.0% above — clearing it would confirm fresh momentum.
Key IXHL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IXHL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.50 | Sell | $3.47 | Sell |
| MA 10 | $3.67 | Sell | $3.66 | Sell |
| MA 20 | $4.08 | Sell | $3.83 | Sell |
| MA 50 | $3.63 | Sell | $4.28 | Sell |
| MA 100 | $5.91 | Sell | $5.86 | Sell |
| MA 200 | $9.56 | Sell | $10.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.70 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -123.42 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -29.04 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -0.42 | Sell |
| Ultimate (7,14,28) | 9.13 | Buy |
| Momentum (10) | -0.65 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 3.32 | Sell |
| ADX (14) | 19.08 | Neutral |
| ATR (14) | 0.15 | Info |
Near term, the technical setup is bearish. RSI14 is 30, and the price trades below the 50-day simple moving average of $3.63 while well below the 200-day simple moving average of $9.56, signaling downward pressure.
The price has support at $3.25 and resistance at $4.91, with a 30-day range from $2.37 to $4.46. The near-term volatility is reflected in an annualized volatility of 90%. These factors point to a fragile short-term footing, with limited upside unless the price breaks through the defined resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.56 | $3.25 | $5.35 | 0% | Neutral | |
| $2.97 | $4.05 | $5.95 | +25% | Bullish | |
| $2.81 | $4.03 | $6.27 | +24% | Bullish | |
| $2.80 | $4.20 | $6.82 | +29% | Bullish | |
| $2.28 | $3.57 | $6.01 | +10% | Neutral | |
| $2.26 | $3.66 | $6.37 | +13% | Neutral | |
| $2.23 | $3.76 | $6.72 | +16% | Neutral | |
| $2.44 | $4.24 | $7.79 | +31% | Bullish | |
| $3.11 | $5.59 | $10.51 | +72% | Bullish | |
| $2.92 | $5.43 | $10.42 | +67% | Bullish | |
| $2.93 | $6.35 | $13.31 | +95% | Bullish | |
| $5.08 | $11.30 | $25.99 | +248% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.56 | $3.25 | $3.84 | +0.00% |
| June 2026 | $2.59 | $3.10 | $3.82 | -4.77% |
| July 2026 | $2.59 | $3.14 | $3.97 | +1.46% |
| August 2026 | $2.78 | $3.41 | $4.38 | +8.54% |
| September 2026 | $2.80 | $3.47 | $4.52 | +1.78% |
| October 2026 | $2.77 | $3.47 | $4.58 | -0.05% |
| November 2026 | $2.96 | $3.73 | $4.99 | +7.70% |
| December 2026 | $3.12 | $3.97 | $5.35 | +6.19% |
Click any year to see its month-by-month IXHL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Incannex Healthcare Inc.'s 2026 outlook centres on $3.25, within a $2.56 to $5.35 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, IXHL could reach as high as $5.95, with a base case around $4.05 and support toward $2.97 — roughly +25% from $3.25. Buyers look set to stay in control over this stretch.
Expect IXHL to range from $2.81 to $6.27 through 2028. The $4.03 average target implies a +24% move from current prices. That is 0% versus the projected 2027 average. Momentum favours further upside here.
The IXHL price prediction for 2029 points to an average of $4.20 (low $2.80, high $6.82) — a potential gain of +29% on today's $3.25. Buyers look set to stay in control over this stretch.
In 2030, IXHL is projected to trade between $2.28 and $6.01, averaging $3.57 — a potential gain of +10% from today's $3.25. That is -15% versus the projected 2029 average. Price action looks broadly range-bound.
Incannex Healthcare Inc.'s 2031 outlook centres on $3.66, within a $2.26 to $6.37 range. That is up +3% on the projected 2030 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, IXHL could reach as high as $6.72, with a base case around $3.76 and support toward $2.23 — roughly +16% from $3.25. Price action looks broadly range-bound.
Expect IXHL to range from $2.44 to $7.79 through 2033. The $4.24 average target implies a +31% move from current prices. That is up +13% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The IXHL price prediction for 2034 points to an average of $5.59 (low $3.11, high $10.51) — a potential gain of +72% on today's $3.25. Momentum favours further upside here.
In 2035, IXHL is projected to trade between $2.92 and $10.42, averaging $5.43 — a potential gain of +67% from today's $3.25. That is -3% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Incannex Healthcare Inc.'s 2040 outlook centres on $6.35, within a $2.93 to $13.31 range. That is up +17% on the projected 2035 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2050, IXHL could reach as high as $25.99, with a base case around $11.30 and support toward $5.08 — roughly +248% from $3.25. Buyers look set to stay in control over this stretch.
Investing $1,000 in IXHL today (≈ 307.692308 IXHL) could be worth
$3,476.47
+$2,476.47 (+248%) by 2050 · US Dollar
Based on the average projected IXHL price of $11.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IXHLwould be worth at today's price.
$1,000 invested in IXHL on May 27, 2025 (≈ 123.456784 IXHL) would be worth
$401.23
-$598.77 (-59.9%) today · 0.40× · US Dollar
Based on a IXHL entry price of $8.1 vs. today's $3.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.71 | $876.01 | -12.4% |
| 1 month ago | $4.07 | $798.53 | -20.1% |
| 3 months ago | $5.01 | $648.7 | -35.1% |
| 6 months ago | $10.8 | $300.93 | -69.9% |
| 1 year ago | $8.1 | $401.23 | -59.9% |
| All time (4.2y) ago | $1,785.6 | $1.82 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IXHL forecast.
Our base-case forecast reaches $6.50 around 2050.
Implied market cap at $6.50: $77.77M
The multi-year forecast shows meaningful upside potential from the current level, with the average price rising through late decade and into the 2040s and 2050. In 2027 the average price is $4.05 (ROI 24.5) and in 2028 it is $4.03 (ROI 24). In 2029 the average price reaches $4.20 (ROI 29.2).
By 2030 the average is $3.57 (ROI 9.7) with a neutral outlook, and by 2033 the average rises to $4.24 (ROI 30.6).
The books show notable acceleration later on, with 2034 average $5.59 (ROI 72.1) and 2035 average $5.43 (ROI 67.2), followed by 2040 average $6.35 (ROI 95.4) and 2050 average $11.30 (ROI 247.7). The bullish sentiment in these years is accompanied by higher max projections, including a 2034 max of $10.51 and a 2050 max of $25.99. These figures illustrate substantial upside potential but also highlight the extended horizon and risk given the early-stage nature and volatility of the sector.
Tap a question to reveal the answer.
The forecast for 2030 shows min $2.28, avg $3.57, max $6.01 with ROI 9.7 and sentiment NEUTRAL.
Near term shows neutral outlook with 2026 avg $3.25 and ROI 0, but longer horizons carry bullish sentiment in 2027–2029 and again in later years, with higher avg prices and ROI up to 247.7 by 2050.
Yes. The 2034 max is $10.51, the 2040 max is $13.31, and the 2050 max is $25.99, indicating potential to exceed $10 in multiple future years.
Current price is $3.25 and market cap is $38.88M.
The 30-day range is $2.37 to $4.46.
Incannex Healthcare Inc. Community Discussion
0Share your Incannex Healthcare Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.